A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761
- First Posted Date
- 2009-12-14
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 24
- Registration Number
- NCT01031472
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2020-01-03
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 50
- Registration Number
- NCT01009814
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India
- Conditions
- First Posted Date
- 2009-10-09
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- ViiV Healthcare
- Registration Number
- NCT00992654
A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-08-03
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 208
- Registration Number
- NCT00951015
- Locations
- 🇪🇸
GSK Investigational Site, Madrid, Spain
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-08-03
- Last Posted Date
- 2015-12-04
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 51
- Registration Number
- NCT00950859
- Locations
- 🇪🇸
GSK Investigational Site, Sevilla, Spain
Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-07-24
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 8
- Registration Number
- NCT00945282
- Locations
- 🇦🇷
GSK Investigational Site, Buenos Aires, Argentina
Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 9
- Registration Number
- NCT00920426
- Locations
- 🇺🇸
GSK Investigational Site, Charlotte, North Carolina, United States
GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 17
- Registration Number
- NCT00867152
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan)
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 68
- Registration Number
- NCT00864474
Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 18
- Registration Number
- NCT00853840
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
© Copyright 2024. All Rights Reserved by MedPath